Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults

Prasad S. Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B.S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T.S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S.R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Chandrashekhar Budhawant, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale, Unknown, Anand Kawade, Arunkumar Gondhali, Mini P. Singh, Ritin Mohindra, Pratibha Pereiera, M R Narayana Murthy, Abhishek V. Raut, Chetna Maliye, Ashwini Kalantri, Vijaya L L Chaudhari, Charuta J Godbole, Malangori Parande, Nandakumar Salunke, Sonali Palkar, Neeta Hanumante, Piyush Chaudhari, Shilpa Karande, Dipti Kumbhar, Shilpa Gupta, Sajal Mitra, S Sudharshini, Prakash Venkatesan, Madhukar -, Abhik Sen, Sunita Sreegiri, Venkata Durga Prasad Vithanala, Tamilanbu Panneerselvam, Aiswarya M Nair, Atul Chaudhari, Silvester Patil

Open source

DOI
10.1080/21645515.2024.2304974
Published
2024-03-21
Container
Human Vaccines & Immunotherapeutics
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/21645515.2024.2304974,
  title = {Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults},
  author = {Prasad S. Kulkarni and Chandrasekaran Padmapriyadarsini and Johan Vekemans and Ashish Bavdekar and Madhu Gupta and Praveen Kulkarni and B.S. Garg and Nithya J. Gogtay and Muralidhar Tambe and Sanjay Lalwani and Kiranjit Singh and Renuka Munshi and Sushant Meshram and T.S. Selvavinayagam and Krishna Pandey and Devi Madhavi Bhimarasetty and S.R. Ramakrishnan and Chetanraj Bhamare and Abhijeet Dharmadhikari and Chandrashekhar Budhawant and Cyrille J. Bonhomme and Madhuri Thakar and Swarali N. Kurle and Elizabeth J. Kelly and Manish Gautam and Nivedita Gupta and Samiran Panda and Balram Bhargava and Cyrus S. Poonawalla and Umesh Shaligram and Dhananjay Kapse and Bhagwat Gunale and Unknown and Anand Kawade and Arunkumar Gondhali and Mini P. Singh and Ritin Mohindra and Pratibha Pereiera and M R Narayana Murthy and Abhishek V. Raut and Chetna Maliye and Ashwini Kalantri and Vijaya L L Chaudhari and Charuta J Godbole and Malangori Parande and Nandakumar Salunke and Sonali Palkar and Neeta Hanumante and Piyush Chaudhari and Shilpa Karande and Dipti Kumbhar and Shilpa Gupta and Sajal Mitra and S Sudharshini and Prakash Venkatesan and Madhukar - and Abhik Sen and Sunita Sreegiri and Venkata Durga Prasad Vithanala and Tamilanbu Panneerselvam and Aiswarya M Nair and Atul Chaudhari and Silvester Patil},
  year = {2024},
  journal = {Human Vaccines \& Immunotherapeutics},
  doi = {10.1080/21645515.2024.2304974},
  url = {https://doi.org/10.1080/21645515.2024.2304974}
}

RIS

TY  - JOUR
TI  - Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
AU  - Prasad S. Kulkarni
AU  - Chandrasekaran Padmapriyadarsini
AU  - Johan Vekemans
AU  - Ashish Bavdekar
AU  - Madhu Gupta
AU  - Praveen Kulkarni
AU  - B.S. Garg
AU  - Nithya J. Gogtay
AU  - Muralidhar Tambe
AU  - Sanjay Lalwani
AU  - Kiranjit Singh
AU  - Renuka Munshi
AU  - Sushant Meshram
AU  - T.S. Selvavinayagam
AU  - Krishna Pandey
AU  - Devi Madhavi Bhimarasetty
AU  - S.R. Ramakrishnan
AU  - Chetanraj Bhamare
AU  - Abhijeet Dharmadhikari
AU  - Chandrashekhar Budhawant
AU  - Cyrille J. Bonhomme
AU  - Madhuri Thakar
AU  - Swarali N. Kurle
AU  - Elizabeth J. Kelly
AU  - Manish Gautam
AU  - Nivedita Gupta
AU  - Samiran Panda
AU  - Balram Bhargava
AU  - Cyrus S. Poonawalla
AU  - Umesh Shaligram
AU  - Dhananjay Kapse
AU  - Bhagwat Gunale
AU  - Unknown
AU  - Anand Kawade
AU  - Arunkumar Gondhali
AU  - Mini P. Singh
AU  - Ritin Mohindra
AU  - Pratibha Pereiera
AU  - M R Narayana Murthy
AU  - Abhishek V. Raut
AU  - Chetna Maliye
AU  - Ashwini Kalantri
AU  - Vijaya L L Chaudhari
AU  - Charuta J Godbole
AU  - Malangori Parande
AU  - Nandakumar Salunke
AU  - Sonali Palkar
AU  - Neeta Hanumante
AU  - Piyush Chaudhari
AU  - Shilpa Karande
AU  - Dipti Kumbhar
AU  - Shilpa Gupta
AU  - Sajal Mitra
AU  - S Sudharshini
AU  - Prakash Venkatesan
AU  - Madhukar -
AU  - Abhik Sen
AU  - Sunita Sreegiri
AU  - Venkata Durga Prasad Vithanala
AU  - Tamilanbu Panneerselvam
AU  - Aiswarya M Nair
AU  - Atul Chaudhari
AU  - Silvester Patil
PY  - 2024
JO  - Human Vaccines & Immunotherapeutics
DO  - 10.1080/21645515.2024.2304974
UR  - https://doi.org/10.1080/21645515.2024.2304974
ER  - 

APA

Kulkarni, P. S., Padmapriyadarsini, C., Vekemans, J., Bavdekar, A., Gupta, M., Kulkarni, P., Garg, B., Gogtay, N. J., Tambe, M., Lalwani, S., Singh, K., Munshi, R., Meshram, S., Selvavinayagam, T., Pandey, K., Bhimarasetty, D. M., Ramakrishnan, S., Bhamare, C., Dharmadhikari, A., Budhawant, C., Bonhomme, C. J., Thakar, M., Kurle, S. N., Kelly, E. J., Gautam, M., Gupta, N., Panda, S., Bhargava, B., Poonawalla, C. S., Shaligram, U., Kapse, D., Gunale, B., Unknown, Kawade, A., Gondhali, A., Singh, M. P., Mohindra, R., Pereiera, P., Murthy, M. R. N., Raut, A. V., Maliye, C., Kalantri, A., Chaudhari, V. L. L., Godbole, C. J., Parande, M., Salunke, N., Palkar, S., Hanumante, N., Chaudhari, P., Karande, S., Kumbhar, D., Gupta, S., Mitra, S., Sudharshini, S., Venkatesan, P., -, M., Sen, A., Sreegiri, S., Vithanala, V. D. P., Panneerselvam, T., Nair, A. M., Chaudhari, A., & Patil, S. (2024). Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2024.2304974

Source records